Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

A study to test the effects and safety of palopegteriparatide in adolescents with long-term hypoparathyroidism

A legfontosabb adatok

Ki végzi
Ascendis Pharma Bone Diseases A/S
Hol
Franciaország, Lengyelország, Németország és Románia7 helyszín, 4 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
11 fő, tervezett
Kezdés
2026. ápr. 22.
Várható befejezés
2031. aug. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. május 13.

Ki vehet részt

Életkor
Legfeljebb 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Males and females, 12 to less than 18 years of age at the time of screening (defined as the date of signing informed consent)
  • Participants with postsurgical chronic hypoparathyroidism, or auto-immune, genetic, or idiopathic hypoparathyroidism for at least 26 weeks. Diagnosis of hypoparathyroidism is established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels (Hypocalcemia is defined as a value below the reference range for normal at the performing laboratory. Inappropriately low serum PTH levels are defined as at or below the median value of the reference range for normal at the performing laboratory while the concomitant serum calcium is low. If specific lab results at the time of original diagnosis are not available, as historical diagnosis affirming these two components is adequate for inclusion)
  • Prior to randomization, achieve normal levels of serum 25(OH) vitamin D and magnesium
  • Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 prior to randomization utilizing the 2009 Schwartz equation: eGFR (mL/min/1.73m^2)= 36.5*((Height (cm))/(Serum Creatinine (µmol/L)))
  • Body mass index (BMI) Z-score greater than -2 SDS and below + 3 SDS at Screening
  • Written, signed informed consent provided by parent(s) or legally acceptable representative(s) of the participant, and by the participant if in accordance to local health authority/ethics requirements. Assent from participant obtained in accordance with applicable regulatory requirements
  • Written, signed informed consent provided by parent(s) or legally acceptable representative(s) of the participant, and by the participant if in accordance to local health authority/ethics requirements. Assent from participant obtained in accordance with applicable regulatory requirements

Ki nem vehet részt

  • Female participants who are pregnant, intend to become pregnant, or are lactating. Note: Acceptable, effective contraception is required for sexually active women of childbearing potential during the trial and for 2 weeks after the last dose of investigational product
  • Diagnosed drug or alcohol dependence within 3 years prior to Screening
  • Symptomatic or severe cardiac disease within 26 weeks prior to Screening including but not limited to congestive heart failure, symptomatic or severe valvular disease, myocardial infarction, severe or uncontrolled arrhythmias, bradycardia, symptomatic hypotension, abnormal systolic BP, or poorly controlled hypertension based on age and sex-specific reference ranges
  • Cerebrovascular accident within 5 years prior to Screening
  • Within 26 weeks prior to Screening: acute colic due to nephrolithiasis or acute gout. Note: Participants with asymptomatic renal stones are permitted
  • Participation in any other interventional trial in which receipt of investigational product or device occurred within 8 weeks (or within 5.5 times the half-life of the investigational product) (whichever comes first) prior to Screening
  • Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)] of the investigational product
  • Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
  • Use of PTH-like drugs (whether commercially available or through participation in an investigational trial), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein, within 4 weeks prior to Screening
  • Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.Note: History of seizures that occur in the setting of hypocalcemia is not exclusionary
  • Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than hypoparathyroidism, such as active hyperthyroidism; Paget disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1C >9%, documented HbA1C result drawn within 12 weeks prior to Screening is acceptable); severe and chronic liver, or renal disease; Cushing syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; parathyroid carcinoma within 5 years prior to Screening; acromegaly; or multiple endocrine neoplasia types 1 and 2
  • Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic corticosteroids (other than as replacement therapy). Short course use of steroids (≤2 weeks/year) equivalent to prednisone ≤60 mg/day is permitted
  • Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (>0.5 mg/day), strontium, or cinacalcet hydrochloride, within 12 weeks prior to Screening
  • Use of osteoporosis therapies known to influence calcium and bone metabolism, i.e., bisphosphonate (oral or intravenous [IV]), denosumab, raloxifene, or romosozumab therapies within 2 years prior to Screening
  • Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton
  • Impaired responsiveness to PTH which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
  • Any other reason that in the opinion of the investigator would prevent the participant from completing participation or following the trial schedule

Hol van ez a vizsgálat?

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy of palopegteriparatide in adolescents with chronic hypoparathyroidism

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism
A regiszteradat frissítve
2026. május 13.